Evaluating efficacy of Shirishadi Agad and Virechana Karma in the management of Santamaka Shwasa w.s.r. to Allergic Asthma- A comparative randomized open clinical trial.

All India Institute of Ayurveda0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•Patients of allergic asthma presenting with Tamaka Shwasa lakshna
•Total serum IgE concentration greater than or equal to 30 and less than or equal to 700 Intenational units per millilitre at Visit 0
•History of at least moderate persistent allergic asthma (consistent with Global Initiative for Asthma [GINA] guidelines of more than 1 year in duration on a stable asthma treatment regimen including inhaled corticosteroids for the preceding 4 weeks
•An FEV1 while withholding short acting beta agonists for at least 6 hours and long acting beta agonists for at least 12 hours, of greater than or equal to 75 percentage of the predicted value at Visit 0
•Evidence of reversible airway obstruction, as defined by an increase in FEV1 of more than or equal to 12 percentage between 20 to 30 minutes after 4 puffs (or less at the discretion of the investigator) of inhaled short-acting beta-agonist administration at Visit 0 or within the preceding year
•Pre-specified level of nocturnal asthma symptoms
•Non-smoker for at least 1 year prior to Visit 0, with a smoking history of no more than 10 pack-years (that is 1 pack,20 cigarettes per day for 10 years)

•History of intubation for asthma
•Asthma exacerbation requiring treatment with systemic steroids within the preceding 3 months
•Asthma exacerbation requiring treatment in an emergency department or a hospital admission in the preceding 6 months
•Upper respiratory tract infection or sinusitis within the preceding 4 weeks
•History of an anaphylactic allergic reaction
•History of treatment with immunotherapy to any allergen within past 3 years
•History of aspirin or non steroidal anti inflammatory drug (NSAID) related asthma patients could have been included in NSAIDs use was avoided for the duration of the study

发起方